Pearl Therapeutics, an AstraZeneca group company, is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via metered dose inhalers.

Bevespi Aerosphere™ approved by the US FDA for patients with COPD

Read Full Article